Connect with us

Business

Axim Biotechnologies Inc (OTCMKTS: AXIM) Takes Dr. Laura Periman On Board its Medical Advisory Board

Published

on

Axim Biotechnologies Inc (OTCMKTS: AXIM) is at the helm of affairs. The group recently announced that it had included Dr. Laura Periman in its Medical Advisory Board.

Dr. Periman is a specialist in ocular surface disease and dry eye disease (DED)

With three decades’ experience in medicine, Dr. Periman has spent the last 20 years in clinical practice, besides specializing in ocular surface disease and dry eye disease (DED). At present, she is appointed as Founder and Director of Dry Eye Services and Clinical Research of the Periman Eye Institute, based out of Seattle. In the past, she has worked as principal investigator in ophthalmic clinical research, primarily specializing in treating DED, IPL procedures, and radiofrequency. In addition, Dr. Periman is academically inclined as she is an international lecturer. To her credit, she has reviewed and edited research papers for several medical journals. Furthermore, she has served as a consultant for various ophthalmic pharmaceutical and medical device companies on the corporate front.

With the new addition, Axim Biotechnologies Inc is targeting growth

The Chief Executive Officer of Axim Biotechnologies Inc, John W. Huemoeller II, went on record and stated that the company is targeting to grow from strength to strength with the new addition. Huemoeller II expressed joy in having a world-class DED expert included in the group’s Medical Advisory Board. He stated that Dr. Periman dons many hats as she has a sea of experience as a clinician, investigator, consultant, researcher, editor, and reviewer. The CEO of the group added that the wealth of knowledge that Dr. Periman brings with her could be used to commercialize the company’s ophthalmic diagnostic lab tests besides strengthening the group’s ophthalmic division.

The focus is on treating dry eyes disease as prevalence is high

If numbers are to be believed, the prevalence of dry eyes disease is high, both in the U.S. and across the world. According to the recent data, around 26 million people suffer from this condition in the U.S. alone, and another 300 million individuals are victims of this disease across the globe. Thus, it calls for immediate attention. The fact that this disease affects the young and old, male and female, is a cause of worry.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

FEATURED STORIES